Efficacy of anakinra for refractory acute calcium pyrophosphate crystal arthritis
- 1 December 2012
- journal article
- case report
- Published by Elsevier in Joint Bone Spine
- Vol. 79 (6) , 621-623
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- European League Against Rheumatism recommendations for calcium pyrophosphate deposition. Part I: terminology and diagnosisAnnals of the Rheumatic Diseases, 2011
- EULAR recommendations for calcium pyrophosphate deposition. Part II: ManagementAnnals of the Rheumatic Diseases, 2011
- Blocking interleukin-1β in acute and chronic autoinflammatory diseasesJournal of Internal Medicine, 2010
- Canakinumab for the treatment of acute flares in difficult‐to‐treat gouty arthritis: Results of a multicenter, phase II, dose‐ranging studyArthritis & Rheumatism, 2010
- The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot studyAnnals of the Rheumatic Diseases, 2009
- Anakinra is a possible alternative in the treatment and prevention of acute attacks of pseudogout in end-stage renal failureJoint Bone Spine, 2009
- An update on the epidemiology of calcium pyrophosphate dihydrate crystal deposition diseaseRheumatology, 2009
- Successful treatment of resistant pseudogout with anakinraArthritis & Rheumatism, 2008
- A pilot study of IL-1 inhibition by anakinra in acute goutArthritis Research & Therapy, 2007
- Gout-associated uric acid crystals activate the NALP3 inflammasomeNature, 2006